Armstrong Fleming & Moore Inc Purchases 501 Shares of Eli Lilly and Company $LLY

Armstrong Fleming & Moore Inc increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 196.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 756 shares of the company’s stock after buying an additional 501 shares during the period. Armstrong Fleming & Moore Inc’s holdings in Eli Lilly and Company were worth $590,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Tectonic Advisors LLC raised its stake in Eli Lilly and Company by 0.5% during the second quarter. Tectonic Advisors LLC now owns 4,092 shares of the company’s stock worth $3,190,000 after buying an additional 21 shares during the last quarter. Values Added Financial LLC increased its stake in Eli Lilly and Company by 3.2% in the second quarter. Values Added Financial LLC now owns 914 shares of the company’s stock valued at $712,000 after purchasing an additional 28 shares in the last quarter. Notis McConarty Edward increased its stake in Eli Lilly and Company by 494.4% in the second quarter. Notis McConarty Edward now owns 1,712 shares of the company’s stock valued at $1,335,000 after purchasing an additional 1,424 shares in the last quarter. Cohen Investment Advisors LLC increased its stake in Eli Lilly and Company by 1.5% in the second quarter. Cohen Investment Advisors LLC now owns 10,866 shares of the company’s stock valued at $8,470,000 after purchasing an additional 156 shares in the last quarter. Finally, Trifecta Capital Advisors LLC increased its stake in Eli Lilly and Company by 12.3% in the second quarter. Trifecta Capital Advisors LLC now owns 24,781 shares of the company’s stock valued at $19,317,000 after purchasing an additional 2,712 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a research note on Sunday, August 17th. Guggenheim lifted their price target on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a research note on Wednesday. Morgan Stanley decreased their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, HSBC boosted their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $943.00.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Jamere Jackson bought 200 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $845.55 on Thursday. The company’s 50 day moving average is $738.69 and its 200-day moving average is $766.57. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market cap of $800.28 billion, a P/E ratio of 55.26, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the firm posted $3.92 earnings per share. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.